The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review
Top Cited Papers
Open Access
- 3 July 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1416403
Abstract
Diabetic cardiomyopathy (DCM) is a myocardial-specific microvascular disease caused by diabetes that affects the structure and function of the heart and is considered to be the leading cause of morbidity and death in patients with diabetes. Currently, there is no specific treatment or preventive drug for DCM, and there is an urgent need to develop new drugs to treat DCM. Traditional Chinese medicine (TCM) has rich experience in the treatment of DCM, and its characteristics of multi-target, multi-pathway, multi-component, and few side effects can effectively deal with the complexity and long-term nature of DCM. Growing evidence suggests that myocardial fibrosis, inflammation, oxidative stress, apoptosis, cardiac hypertrophy, and advanced glycation end product deposition were the main pathologic mechanisms of DCM. According to the pathological mechanism of DCM, this study revealed the potential of metabolites and prescriptions in TCM against DCM from the perspective of signaling pathways. The results showed that TGF-β/Smad, NF-κB, PI3K/AKT, Nrf2, AMPK, NLRP3, and Wnt/β-catenin signaling pathways were the key signaling pathways for TCM treatment of DCM. The aim of this study was to summarize and update the signaling pathways for TCM treatment of DCM, to screen potential targets for drug candidates against DCM, and to provide new ideas and more experimental evidence for the clinical use of TCM treatment of DCM.Keywords
This publication has 74 references indexed in Scilit:
- Interplay Between TGF-β Signaling and MicroRNA in Diabetic CardiomyopathyCardiovascular Drugs and Therapy, 2023
- Wnt/β-catenin signaling pathway-a versatile player in apoptosis and autophagyBiochimie, 2023
- Oxymatrine and insulin resistance: Focusing on mechanistic intricacies involve in diabetes associated cardiomyopathy via SIRT1/AMPK and TGF‐β signaling pathwayJournal of Biochemical and Molecular Toxicology, 2023
- Syringaresinol protects against diabetic nephropathy by inhibiting pyroptosis via NRF2-mediated antioxidant pathwayCell Biology and Toxicology, 2023
- Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent InflammationAdvanced Science, 2022
- NF-κB, A Potential Therapeutic Target in Cardiovascular DiseasesCardiovascular Drugs and Therapy, 2022
- Interplay between PI3K/AKT pathway and heart disordersMolecular Biology Reports, 2022
- Role of PI3K/Akt signaling pathway in cardiac fibrosisMolecular and Cellular Biochemistry, 2021
- Si-Miao-Yong-An decoction preserves cardiac function and regulates GLC/AMPK/NF-κB and GLC/PPARα/PGC-1α pathways in diabetic miceBiomedicine & Pharmacotherapy, 2020
- Syringaresinol Protects against Type 1 Diabetic Cardiomyopathy by Alleviating Inflammation Responses, Cardiac Fibrosis, and Oxidative StressMolecular Nutrition & Food Research, 2020